Luc Zimmer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3738932/publications.pdf

Version: 2024-02-01

146	4,587	81900	123424
papers	citations	39 h-index	61 g-index

164	164	164	4597
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Translating biased agonists from molecules to medications: Serotonin 5-HT1A receptor functional selectivity for CNS disorders. , 2022, 229, 107937.		35
2	Comparative diagnosis interest of NfL and pNfH in CSF and plasma in a context of FTDâ€“ALS spectrum. Journal of Neurology, 2022, 269, 1522-1529.	3.6	7
3	PET Metabolic Imaging of Time-Dependent Reorganization of Olfactory Cued Fear Memory Networks in Rats. Cerebral Cortex, 2022, 32, 2717-2728.	2.9	8
4	Impaired Local and Long-Range Brain Connectivity and Visual Response in a Genetic Rat Model of Hyperactivity Revealed by Functional Ultrasound. Frontiers in Neuroscience, 2022, 16, 865140.	2.8	0
5	Experimental neuropsychopharmacology, yesterday, today and tomorrow. A conversation with Michel Hamon. Therapie, 2021, 76, 63-66.	1.0	0
6	Clinical research in psychopharmacology, the current situation and its perspectives. A conversation with Pierre-Michel Llorca. Therapie, 2021, 76, 67-70.	1.0	0
7	The contrasting landscape of drug discovery in neuropsychopharmacology. A conversation with Adrian Newman-Tancredi. Therapie, 2021, 76, 71-74.	1.0	0
8	How to improve in France ADHD transition support from childhood to adulthood. L'Encephale, 2021, 47, 187-188.	0.9	0
9	Innovative approaches in CNS drug discovery. Therapie, 2021, 76, 101-109.	1.0	11
10	Cluster headache: state of the art of pharmacological treatments and therapeutic perspectives. Fundamental and Clinical Pharmacology, 2021, 35, 595-619.	1.9	6
11	Towards in vivo imaging of functionally active 5-HT1A receptors in schizophrenia: concepts and challenges. Translational Psychiatry, 2021, 11, 22.	4.8	11
12	Neuropsychopharmacology, a challenge for the understanding of the thinking brain and its future therapies. Therapie, 2021, 76, 61-62.	1.0	0
13	[18F]F13640, a 5-HT1A Receptor Radiopharmaceutical Sensitive to Brain Serotonin Fluctuations. Frontiers in Neuroscience, 2021, 15, 622423.	2.8	5
14	Ozone Atmospheric Pollution and Alzheimerâ€™s Disease: From Epidemiological Facts to Molecular Mechanisms. Advances in Alzheimer's Disease, 2021, , .	0.2	0
15	Inter-subject registration and application of the SIGMA rat brain atlas for regional labeling in functional ultrasound imaging. Journal of Neuroscience Methods, 2021, 355, 109139.	2.5	4
16	Fundamental and clinical neuropharmacology, a terra incognita with constantly expanding frontiers. Fundamental and Clinical Pharmacology, 2021, 35, 501-505.	1.9	1
17	Different Alterations of Agonist and Antagonist Binding to 5-HT1A Receptor in a Rat Model of Parkinsonâ€™s Disease and Levodopa-Induced Dyskinesia: A MicroPET Study. Journal of Parkinson's Disease, 2021, 11, 1257-1269.	2.8	2
18	18F-F13640 PET imaging of functional receptors in humans. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 220-221.	6.4	16

#	Article	IF	Citations
19	Pharmacological MRI to investigate the functional selectivity of 5-HT1A receptor biased agonists. Neuropharmacology, 2020, 172, 107867.	4.1	8
20	Pharmaco-fUS for Characterizing Drugs for Alzheimerâ€™s Disease â€“ The Case of THN201, a Drug Combination of Donepezil Plus Mefloquine. Frontiers in Neuroscience, 2020, 14, 835.	2.8	14
21	Functional ultrasound imaging to study brain dynamics: Application of pharmaco-fUS to atomoxetine. Neuropharmacology, 2020, 179, 108273.	4.1	14
22	Change in Expression of 5-HT6 Receptor at Different Stages of Alzheimerâ€™s Disease: A Postmortem Study with the PET Radiopharmaceutical [18F]2FNQ1P. Journal of Alzheimer's Disease, 2020, 75, 1329-1338.	2.6	1
23	Bayesian Estimation of the ntPET Model in Single-Scan Competition PET Studies. Frontiers in Physiology, 2020, 11, 498.	2.8	8
24	MAPSSIC, a communicating MAPS-based intracerebral positrons probe for deep brain imaging in awake and freely-moving rats. EPJ Web of Conferences, 2020, 225, 09002.	0.3	0
25	Preclinical validation of [18F]2FNQ1P as a specific PET radiotracer of 5-HT6 receptors in rat, pig, non-human primate and human brain tissue. Nuclear Medicine and Biology, 2020, 82-83, 57-63.	0.6	5
26	PET imaging of the influence of physiological and pathological Î±-synuclein on dopaminergic and serotonergic neurotransmission in mouse models. CNS Neuroscience and Therapeutics, 2019, 25, 57-68.	3.9	8
27	Evaluation of Myelin Radiotracers in the Lysolecithin Rat Model of Focal Demyelination: Beware of Pitfalls!. Contrast Media and Molecular Imaging, 2019, 2019, 1-10.	0.8	7
28	MAPSSIC, a Novel CMOS Intracerebral Positrons Probe for Deep Brain Imaging in Awake and Freely Moving Rats: A Monte Carlo Study. IEEE Transactions on Radiation and Plasma Medical Sciences, 2019, 3, 302-314.	3.7	3
29	Contrast Media & Molecular Imaging, a Journal at the Crossroads of the Scientific and Medical Disciplines of Biomedical Imaging. Contrast Media and Molecular Imaging, 2019, 2019, 1-2.	0.8	0
30	Is There a Role for GPCR Agonist Radiotracers in PET Neuroimaging?. Frontiers in Molecular Neuroscience, 2019, 12, 255.	2.9	29
31	Serotonin 5-HT_{1A} Receptor Biased Agonists Induce Different Cerebral Metabolic Responses: A [¹⁸F]-Fluorodesoxyglucose Positron Emission Tomography Study in Conscious and Anesthetized Rats. ACS Chemical Neuroscience, 2019, 10, 3108-3119.	3.5	15
32	Evaluation of [¹⁸F]2FP3 in pigs and nonâ€human primates. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 34-42.	1.0	12
33	Ozone Atmospheric Pollution and Alzheimerâ€™s Disease: From Epidemiological Facts to Molecular Mechanisms. Journal of Alzheimer's Disease, 2018, 62, 503-522.	2.6	46
34	18F-F13640 preclinical evaluation in rodent, cat and primate as a 5-HT1A receptor agonist for PET neuroimaging. Brain Structure and Function, 2018, 223, 2973-2988.	2.3	21
35	Implantable CMOS pixel sensor for positron imaging in rat brain. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2018, 911, 19-24.	1.6	3
36	Amyloid-Beta Radiotracer [18F]BF-227 Does Not Bind to Cytoplasmic Glial Inclusions of Postmortem Multiple System Atrophy Brain Tissue. Contrast Media and Molecular Imaging, 2018, 2018, 1-7.	0.8	11

#	Article	IF	Citations
37	Benzodiazepine dose reduction in prisoner patients: 15Âyears' teamwork between psychiatrists and pharmacists. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 807-812.	1.5	8
38	In Silico, in Vitro, and in Vivo Evaluation of New Candidates for Î±-Synuclein PET Imaging. Molecular Pharmaceutics, 2018, 15, 3153-3166.	4.6	40
39	In vivo biased agonism at 5-HT1A receptors: characterisation by simultaneous PET/MR imaging. Neuropsychopharmacology, 2018, 43, 2310-2319.	5.4	27
40	The in Vitro Actions of Loxapine on Dopaminergic and Serotonergic Receptors. Time to Consider Atypical Classification of This Antipsychotic Drug?. International Journal of Neuropsychopharmacology, 2018, 21, 355-360.	2.1	6
41	Activity in the rat olfactory cortex is correlated with behavioral response to odor: a microPET study. Brain Structure and Function, 2017, 222, 577-586.	2.3	14
42	Quantitative longitudinal imaging of activated microglia as a marker of inflammation in the pilocarpine rat model of epilepsy using [¹¹C]-(R)-PK11195 PET and MRI. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 1251-1263.	4.3	24
43	Contribution of Clinical Neuroimaging to the Understanding of the Pharmacology of Methylphenidate. Trends in Pharmacological Sciences, 2017, 38, 608-620.	8.7	20
44	Oxytocin and Serotonin Brain Mechanisms in the Nonhuman Primate. Journal of Neuroscience, 2017, 37, 6741-6750.	3.6	52
45	[11 C]PF-3274167 as a PET radiotracer of oxytocin receptors: Radiosynthesis and evaluation in rat brain. Nuclear Medicine and Biology, 2017, 55, 1-6.	0.6	5
46	Hippocampal 5-HT1A receptor expression changes in prodromal stages of Alzheimer's disease: Beneficial or deleterious?. Neuropharmacology, 2017, 123, 446-454.	4.1	22
47	Characterization and Reliability of [18F]2FNQ1P in Cynomolgus Monkeys as a PET Radiotracer for Serotonin 5-HT6 Receptors. Frontiers in Pharmacology, 2017, 8, 471.	3.5	10
48	IMIC â€" needle-shaped low-power monolithic active pixel sensor for molecular neuroimaging on awake and freely moving rats. , 2016, , .		0
49	A microPET comparison of the effects of etifoxine and diazepam on [11 C]flumazenil uptake in rat brains. Neuroscience Letters, 2016, 612, 74-79.	2.1	6
50	Agonist and antagonist bind differently to 5-HT1A receptors during Alzheimerâ€™s disease: A post-mortem study with PET radiopharmaceuticals. Neuropharmacology, 2016, 109, 88-95.	4.1	34
51	Marmoset Serotonin 5-HT_{1A}Receptor Mapping with a Biased Agonist PET Probe¹⁸F-F13714: Comparison with an Antagonist Tracer¹⁸F-MPPF in Awake and Anesthetized States. International Journal of Neuropsychopharmacology, 2016, 19, pyw079.	2.1	22
52	Selective serotonin 5-HT1A receptor biased agonists elicitdistinct brain activation patterns: a pharmacoMRI study. Scientific Reports, 2016, 6, 26633.	3.3	47
53	Imaging Dopamine and Serotonin Systems on MPTP Monkeys: A Longitudinal PET Investigation of Compensatory Mechanisms. Journal of Neuroscience, 2016, 36, 1577-1589.	3.6	42
54	Differential effects of amyloid-beta 1â€“40 and 1â€“42 fibrils on 5-HT 1A serotonin receptors in rat brain. Neurobiology of Aging, 2016, 40, 11-21.	3.1	24

#	Article	IF	Citations
55	Pharmacological agonists for more-targeted CNS radio-pharmaceuticals. Oncotarget, 2016, 7, 80111-80112.	1.8	10
56	PIXSIC: A Wireless Intracerebral Radiosensitive Probe in Freely Moving Rats. Molecular Imaging, 2015, 14, 7290.2015.00020.	1.4	7
57	Selective trifluoromethylthiolation of heteroaromatic sp2 Câ€“H bonds with the 2nd generation of trifluoromethanesulfenamide reagent. Journal of Fluorine Chemistry, 2015, 171, 78-81.	1.7	41
58	Preclinical evaluation of [18F]2FNQ1P as the first fluorinated serotonin 5-HT6 radioligand for PET imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 495-502.	6.4	17
59	PIXSIC, a Pixelated Î²+-Sensitive Probe for Radiopharmacological Investigations in Rat Brain: Binding Studies with [18F]MPPF. Molecular Imaging and Biology, 2015, 17, 163-167.	2.6	4
60	A Multi-Atlas Based Method for Automated Anatomical Rat Brain MRI Segmentation and Extraction of PET Activity. PLoS ONE, 2014, 9, e109113.	2.5	40
61	A Postmortem Study to Compare Agonist and Antagonist 5â€<scp>HT</scp>_{1A} Receptorâ€binding Sites in Alzheimer's Disease. CNS Neuroscience and Therapeutics, 2014, 20, 930-934.	3.9	20
62	Synthesis and pharmacological evaluation of a new series of radiolabeled ligands for 5-HT7 receptor PET neuroimaging. Nuclear Medicine and Biology, 2014, 41, 330-337.	0.6	21
63	Electrophilic Trifluoromethylthiolation of Carbonyl Compounds. Chemistry - A European Journal, 2014, 20, 8589-8593.	3.3	129
64	Molecular imaging of the serotonin 5-HT7 receptors: from autoradiography to positron emission tomography. Reviews in the Neurosciences, 2014, 25, 357-65.	2.9	6
65	Syntheses, Radiolabelings, and in Vitro Evaluations of Fluorinated PET Radioligands of 5-HT₆ Serotoninergic Receptors. Journal of Medicinal Chemistry, 2014, 57, 3884-3890.	6.4	54
66	Binding of the PET Radiotracer [¹⁸F]BF227 Does not Reflect the Presence of Alpha-Synuclein Aggregates in Transgenic Mice. Current Alzheimer Research, 2014, 11, 955-960.	1.4	13
67	Outcome of Poor-Grade Subarachnoid Hemorrhage as Determined by Biomarkers of Glucose Cerebral Metabolism. Neurocritical Care, 2013, 18, 234-244.	2.4	13
68	Radiosynthesis and in vivo evaluation of fluorinated huprine derivates as PET radiotracers of acetylcholinesterase. Nuclear Medicine and Biology, 2013, 40, 554-560.	0.6	4
69	Current status of positron emission tomography radiotracers for serotonin receptors in humans. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 105-113.	1.0	22
70	A wireless beta-microprobe based on pixelated silicon forin vivobrain studies in freely moving rats. Physics in Medicine and Biology, 2013, 58, 4483-4500.	3.0	7
71	Ultra high performance liquid chromatography as a tool for the discovery and the analysis of biomarkers of diseases: A review. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 927, 37-53.	2.3	62
72	Baseâ€Catalyzed Electrophilic Trifluoromethylthiolation of Terminal Alkynes. Angewandte Chemie - International Edition, 2013, 52, 10814-10817.	13.8	137

#	Article	IF	Citations
73	PET Radiotracers for Molecular Imaging of Serotonin 5-HT_{1A} Receptors. Current Medicinal Chemistry, 2013, 21, 70-81.	2.4	22
74	Radiosynthesis and Preclinical Evaluation of 18F-F13714 as a Fluorinated 5-HT1A Receptor Agonist Radioligand for PET Neuroimaging. Journal of Nuclear Medicine, 2012, 53, 969-976.	5.0	24
75	Genetic association between helpless trait and depression-related phenotypes: evidence from crossbreeding studies with H/Rouen and NH/Rouen mice. International Journal of Neuropsychopharmacology, 2012, 15, 363-374.	2.1	9
76	MPTP <scp>A</scp>nimal <scp>M</scp>odel of <scp>P</scp>arkinsonism: <scp>D</scp>opamine <scp>C</scp>ell <scp>D</scp>eath or <scp>O</scp>nly <scp>T</scp>yrosine <scp>H</scp>ydroxylase <scp>I</scp>mpairment? â€“ <scp>A S</scp>tudy <scp>U</scp>sing <scp>PET I</scp>maging, <scp>A</scp>utoradiography, and <scp>I</scp>mmunohistochemistry in the <scp>C</scp>at. CNS Neuroscience and Therapeutics, 2012, 18, 934-941.	3.9	20
77	PET radiotracers for molecular imaging in the brain: Past, present and future. NeuroImage, 2012, 61, 363-370.	4.2	83
78	Enhanced Anxiety Observed in Cocaine Withdrawn Rats Is Associated with Altered Reactivity of the Dorsomedial Prefrontal Cortex. PLoS ONE, 2012, 7, e43535.	2.5	28
79	Internalization of serotonin 5â€HT_{1A} autoreceptors as an imaging biomarker of antidepressant response. Environmental Sciences Europe, 2012, 1, 239-245.	5.5	2
80	Effects of amyloid-Î² peptides on the serotoninergic 5-HT1A receptors in the rat hippocampus. Neurobiology of Aging, 2011, 32, 103-114.	3.1	19
81	Impact of pharmacist and clinician dual intervention on prescribed benzodiazepines in prisoner patients: a retrospective study. Fundamental and Clinical Pharmacology, 2011, 25, 762-767.	1.9	9
82	Behaviour of a genetic mouse model of depression in the learned helplessness paradigm. Psychopharmacology, 2011, 215, 595-605.	3.1	16
83	Synthesis and biological evaluation of potential 5-HT7 receptor PET radiotracers. European Journal of Medicinal Chemistry, 2011, 46, 3455-3461.	5.5	26
84	Genetic Inactivation of Prokineticin Receptor-1 Leads to Heart and Kidney Disorders. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 842-850.	2.4	24
85	Comparison of 4 Radiolabeled Antagonists for Serotonin 5-HT₇ Receptor Neuroimaging: Toward the First PET Radiotracer. Journal of Nuclear Medicine, 2011, 52, 1811-1818.	5.0	37
86	[18F]F15599, a novel 5-HT1A receptor agonist, as a radioligand for PET neuroimaging. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 594-605.	6.4	42
87	Looking for a 5-HT7 radiotracer for positron emission tomography. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3730-3733.	2.2	23
88	Small-animal positron emission tomography as a tool for neuropharmacology. Trends in Pharmacological Sciences, 2010, 31, 411-417.	8.7	103
89	F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: Influence on neuronal firing and neurotransmitter release. European Journal of Pharmacology, 2009, 607, 74-83.	3.5	9
90	MicroPET imaging of 5-HT1A receptors in rat brain: a testâ€“retest [18F]MPPF study. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 53-62.	6.4	16

#	Article	IF	Citations
91	Positron emission tomography neuroimaging for a better understanding of the biology of ADHD. Neuropharmacology, 2009, 57, 601-607.	4.1	44
92	Functional correlates for 5-HT1A receptors in maternally deprived rats displaying anxiety and depression-like behaviors. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 262-268.	4.8	54
93	In-capillary derivatization and capillary electrophoresis separation of amino acid neurotransmitters from brain microdialysis samples. Journal of Chromatography A, 2008, 1205, 144-149.	3.7	44
94	Can positron emission tomography facilitate paediatric drug development?. Fundamental and Clinical Pharmacology, 2008, 22, 595-598.	1.9	5
95	Decreased [18F]MPPF Binding Potential in the Dorsal Raphe Nucleus After a Single Oral Dose of Fluoxetine: A Positron-Emission Tomography Study in Healthy Volunteers. Biological Psychiatry, 2008, 63, 1135-1140.	1.3	41
96	Unchanged density of 5-HT1A autoreceptors on the plasma membrane of nucleus raphe dorsalis neurons in rats chronically treated with fluoxetine. Neuroscience, 2008, 151, 692-700.	2.3	30
97	Acute ethanol induces Fos in GABAergic and non-GABAergic forebrain neurons: A double-labeling study in the medial prefrontal cortex and extended amygdala. Neuroscience, 2008, 153, 259-267.	2.3	40
98	P.2.b.010 PKC blockade prevents the in vivo allosteric modulation of the 5-HT transporter induced by escitalopram. European Neuropsychopharmacology, 2008, 18, S318-S319.	0.7	0
99	A distinct [18F]MPPF PET profile in amnestic mild cognitive impairment compared to mild Alzheimer's disease. NeuroImage, 2008, 40, 1251-1256.	4.2	50
100	Toward a quantification of extracellular brain endogenous serotonin concentration with [18F]MPPF in a multi-injection PET protocol. NeuroImage, 2008, 41, T149.	4.2	1
101	The Potential of a Radiosensitive Intracerebral Probe to Monitor ¹⁸F-MPPF Binding in Mouse Hippocampus In Vivo. Journal of Nuclear Medicine, 2008, 49, 1155-1161.	5.0	5
102	Automated radiosynthesis of the Pittsburg compound-B using a commercial synthesizer. Nuclear Medicine Communications, 2008, 29, 920-926.	1.1	27
103	Test Retest Reproducibility of 18F-MPPF PET in Healthy Humans: A Reliability Study. Journal of Nuclear Medicine, 2007, 48, 1279-1288.	5.0	22
104	Up-regulation of hippocampal serotonin metabolism in mild cognitive impairment. Neurology, 2007, 69, 1012-1017.	1.1	68
105	R-citalopram prevents the neuronal adaptive changes induced by escitalopram. NeuroReport, 2007, 18, 1553-1556.	1.2	32
106	[18F]MPPF as a tool for the in vivo imaging of 5-HT1A receptors in animal and human brain. Neuropharmacology, 2007, 52, 695-707.	4.1	79
107	Synthesis and biological evaluation in rat and cat of [18F]12ST05 as a potential 5-HT6 PET radioligand. Nuclear Medicine and Biology, 2007, 34, 995-1002.	0.6	22
108	Raytest ClearPETâ„¢, a new generation small animal PET scanner. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2007, 571, 498-501.	1.6	44

#	Article	IF	Citations
109	Activation of afferents to the ventral tegmental area in response to acute amphetamine: a doubleâ€labelling study. European Journal of Neuroscience, 2007, 26, 1011-1025.	2.6	62
110	Effects of the serotonin 5-HT7 receptor antagonist SB-269970 on the inhibition of dopamine neuronal firing induced by amphetamine. European Journal of Pharmacology, 2007, 570, 72-76.	3.5	9
111	Simultaneous in vivo magnetic resonance imaging and radioactive measurements with the Î²-MicroProbe. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1868-1872.	6.4	9
112	5-HT7 Receptor Antagonists as a New Class of Antidepressants. Drug News and Perspectives, 2007, 20, 613.	1.5	58
113	Increased serotonin receptor availability in human sleep: Evidence from an [18F]MPPF PET study in narcolepsy. NeuroImage, 2006, 30, 341-348.	4.2	47
114	A PET imaging study of 5-HT1A receptors in cat brain after acute and chronic fluoxetine treatment. NeuroImage, 2006, 33, 834-842.	4.2	46
115	A comparison of in vivo and in vitro neuroimaging of 5-HT1A receptor binding sites in the cat brain. Journal of Chemical Neuroanatomy, 2006, 31, 226-232.	2.1	27
116	Chloramphenicol decreases brain glucose utilization and modifies the sleep-wake cycle architecture in rats. Journal of Neurochemistry, 2005, 93, 1623-1632.	3.9	9
117	A new multimodality system for quantitative in vivo studies in small animals: combination of nuclear magnetic resonance and the radiosensitive /spl beta/-MicroProbe. IEEE Transactions on Nuclear Science, 2005, 52, 1281-1287.	2.0	2
118	A 18F-MPPF PET normative database of 5-HT1A receptor binding in men and women over aging. Journal of Nuclear Medicine, 2005, 46, 1980-9.	5.0	85
119	Acute Treatment with the Antidepressant Fluoxetine Internalizes 5-HT1A Autoreceptors and Reduces the In Vivo Binding of the PET Radioligand [18F]MPPF in the Nucleus Raphe Dorsalis of Rat. Journal of Neuroscience, 2004, 24, 5420-5426.	3.6	129
120	The ANIMAGE project: a multimodal imaging platform for small animal research. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2004, 527, 117-123.	1.6	2
121	Combining the radiosensitive Beta MicroProbe to Nuclear Magnetic Resonance: theoretical approach for in vivo studies in small animals. Journal of Neuroscience Methods, 2004, 140, 47-52.	2.5	7
122	Toward brain imaging of serotonin 5-HT1A autoreceptor internalization. NeuroImage, 2004, 22, 1421-1421.	4.2	0
123	Toward brain imaging of serotonin 5-HT1A autoreceptor internalization. NeuroImage, 2004, 22, 1421-1426.	4.2	54
124	PET study of the [11 C]raclopride binding in the striatum of the awake cat: effects of anaesthetics and role of cerebral blood flow. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 141-148.	6.4	64
125	Displacement of the PET ligand18F-MPPF by the electrically evoked serotonin release in the rat hippocampus. Synapse, 2003, 49, 239-245.	1.2	29
126	Carbon-11 labelling of 8{{3-[4-(2-[11C]methoxyphenyl)piperazin-1-yl]-2-hydroxypropyl}oxy}thiochroman, a presynaptic 5-HT1A receptor agonist, and its in vivo evaluation in anaesthetised rat and in awake cat. Nuclear Medicine and Biology, 2003, 30, 541-546.	0.6	32

#	Article	IF	Citations
127	A reduced extracellular serotonin level increases the 5-HT1A PET ligand 18F-MPPF binding in the rat hippocampus. Journal of Nuclear Medicine, 2003, 44, 1495-501.	5.0	35
128	Neither the density nor function of striatal dopamine transporters were influenced by chronic n-3 polyunsaturated fatty acid deficiency in rodents. Neuroscience Letters, 2002, 321, 95-99.	2.1	33
129	The dopamine mesocorticolimbic pathway is affected by deficiency in nâˆ’3 polyunsaturated fatty acids. American Journal of Clinical Nutrition, 2002, 75, 662-667.	4.7	197
130	The potential of the Î²-Microprobe, an intracerebral radiosensitive probe, to monitor the [18F]MPPF binding in the rat dorsal raphe nucleus. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 1237-1247.	6.4	27
131	Effects of subthalamic nucleus stimulation on actual and imagined movement in Parkinson's disease : a PET study. Journal of Neurology, 2002, 249, 1689-1698.	3.6	64
132	Effect of endogenous serotonin on the binding of the 5-HT1A PET ligand 18F-MPPF in the rat hippocampus: kinetic beta measurements combined with microdialysis. Journal of Neurochemistry, 2002, 80, 278-286.	3.9	78
133	Modeling [18F]MPPF Positron Emission Tomography Kinetics for the Determination of 5-Hydroxytryptamine(1A) Receptor Concentration with Multiinjection. Journal of Cerebral Blood Flow and Metabolism, 2002, 22, 753-765.	4.3	58
134	Short- and long-term effects of p-ethynylphenylalanine on brain serotonin levels. Neurochemical Research, 2002, 27, 269-275.	3.3	18
135	SIC, an intracerebral beta(+)-range-sensitive probe for radiopharmacology investigations in small laboratory animals: binding studies with (11)C-raclopride. Journal of Nuclear Medicine, 2002, 43, 227-33.	5.0	15
136	Polyunsaturated fatty acids and cerebral function: Focus on monoaminergic neurotransmission. Lipids, 2001, 36, 937-944.	1.7	161
137	Large scale production of 6â€[¹⁸F]fluoroâ€Lâ€DOPA in a semiâ€automated system. Journal of Labelled Compounds and Radiopharmaceuticals, 2001, 44, S868.	1.0	7
138	Microdialysis as a tool for in vivo study of dopamine transporter function in rat brains. Journal of Neuroscience Methods, 2000, 103, 137-144.	2.5	9
139	Chronic n-3 polyunsaturated fatty acid deficiency alters dopamine vesicle density in the rat frontal cortex. Neuroscience Letters, 2000, 284, 25-28.	2.1	155
140	Modification of dopamine neurotransmission in the nucleus accumbens of rats deficient in nâ€“3 polyunsaturated fatty acids. Journal of Lipid Research, 2000, 41, 32-40.	4.2	181
141	Modification of dopamine neurotransmission in the nucleus accumbens of rats deficient in n-3 polyunsaturated fatty acids. Journal of Lipid Research, 2000, 41, 32-40.	4.2	156
142	n-3 polyunsaturated fatty acid deficiency and dopamine metabolism in the rat frontal cortex. Lipids, 1999, 34, S251-S251.	1.7	24
143	Prominent Role ofnâ€”3 Polyunsaturated Fatty Acids in Cortical Dopamine Metabolism. Nutritional Neuroscience, 1999, 2, 257-265.	3.1	17
144	Pharmacological characterization of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)n ortropane as a selective and potent inhibitor of the neuronal dopamine transporter. Journal of Pharmacology and Experimental Therapeutics, 1999, 291, 648-54.	2.5	51

#	Article	IF	Citations
145	Chronic n-3 polyunsaturated fatty acid diet-deficiency acts on dopamine metabolism in the rat frontal cortex: a microdialysis study. Neuroscience Letters, 1998, 240, 177-181.	2.1	110
146	Evolution of dopamine receptors in the rat after neonatal hypoxia-ischemia: Autoradiographic studies. Life Sciences, 1996, 60, 151-162.	4.3	18